News05/10/2026
Prime Medicine begins PM577a clinical trial
Prime Medicine, Inc. →Prime Medicine reported dosing the first participant in its global Phase 1/2 study of PM577a, an investigational Prime Editor for H1069Q-mutated Wilson disease. The trial is designed to assess safety, tolerability and initial clinical efficacy; the announcement does not establish treatment approval.